#17 : Ensacove Enters the Lung Cancer Treatment Arena

The FDA has approved Ensacove (ensartinib), a new second-generation ALK inhibitor, as a first-line treatment for ALK-positive non-small cell lung cancer (NSCLC) in patients who have not previously received an ALK inhibitor. Developed by a subsidiary of China's Betta Pharmaceuticals, Ensacove is the first innovative targeted lung cancer drug from a Chinese company to reach the global market. Clinical trial data from the eXalt3 study showed a 44% reduction in the risk of disease progression or death compared to Xalkori. While Ensacove is entering a market with other established ALK inhibitors, including Roche's Alecensa, which showed a 57% reduction in the risk of disease progression or death, and has also been approved for adjuvant treatment and it represents a significant new treatment option for patients. Hosted on Acast. See acast.com/privacy for more information.